Key Takeaways
- • Algorithmiq raised €18 million in Series B funding co-led by CDP Venture Capital, marking a significant milestone for the quantum software startup focused on commercializing algorithms for quantum computers.
- • The company relocated its headquarters from Helsinki, Finland to Milan, Italy, signaling a strategic shift in geographic positioning and operational base as it scales commercialization efforts.
- • Algorithmiq previously secured €13.7 million in Series A funding in 2023, following an initial $4 million seed round, demonstrating consistent investor confidence in quantum algorithm development.
- • The startup won a $2 million Wellcome Leap Prize for quantum-driven therapeutics, becoming the first company to prove end-to-end quantum-classical algorithms can simulate complex drug interactions—a validation of its technology pathway for healthcare applications.
- • Leadership is anchored by CEO Sabrina Maniscalco, an adjunct professor at Aalto University and quantum information specialist, positioning the company at the intersection of academic research and commercial quantum computing development.
Summary
Algorithmiq, a quantum computing software company specializing in hybrid quantum-classical algorithms, has secured €18 million in Series B funding co-led by CDP Venture Capital. The round reflects growing institutional confidence in the startup's approach to making quantum computing commercially viable for real-world applications, particularly in pharmaceuticals and chemistry.
The capital raise coincides with the company's relocation from Helsinki to Milan, a geographic expansion that underscores Algorithmiq's strategic pivot toward broader European markets and access to deeper institutional capital pools. This move represents a deliberate repositioning as the startup transitions from research-stage development toward production-grade commercialization of its quantum algorithms.
Algorithmiq's funding trajectory demonstrates consistent investor traction. The company previously raised $4 million in seed funding followed by €13.7 million in Series A financing in 2023, establishing a clear pattern of ascending capital rounds as validation metrics improve. The cumulative funding now exceeds €35 million across all rounds, reflecting the quantum computing sector's growing maturity and commercial promise.
Beyond venture capital, Algorithmiq received external validation through a $2 million Wellcome Leap Prize for quantum-driven cancer therapeutics development. The company distinguished itself as the first to demonstrate proof-of-concept for end-to-end quantum-classical algorithm integration capable of simulating complex molecular interactions in drug development. This achievement positions the startup favorably within the $50 million Q4Bio initiative, designed to accelerate quantum algorithm development specifically for human health applications.
Leadership continuity anchors the venture: CEO Sabrina Maniscalco, who maintains an adjunct professorship at Aalto University and holds credentials in quantum information science, bridges the gap between theoretical quantum research and commercial application development. This technical credibility, combined with sustained investor backing, positions Algorithmiq as a central player in translating quantum computing from theoretical potential into practical healthcare and chemistry solutions.
The capital raise coincides with the company's relocation from Helsinki to Milan, a geographic expansion that underscores Algorithmiq's strategic pivot toward broader European markets and access to deeper institutional capital pools. This move represents a deliberate repositioning as the startup transitions from research-stage development toward production-grade commercialization of its quantum algorithms.
Algorithmiq's funding trajectory demonstrates consistent investor traction. The company previously raised $4 million in seed funding followed by €13.7 million in Series A financing in 2023, establishing a clear pattern of ascending capital rounds as validation metrics improve. The cumulative funding now exceeds €35 million across all rounds, reflecting the quantum computing sector's growing maturity and commercial promise.
Beyond venture capital, Algorithmiq received external validation through a $2 million Wellcome Leap Prize for quantum-driven cancer therapeutics development. The company distinguished itself as the first to demonstrate proof-of-concept for end-to-end quantum-classical algorithm integration capable of simulating complex molecular interactions in drug development. This achievement positions the startup favorably within the $50 million Q4Bio initiative, designed to accelerate quantum algorithm development specifically for human health applications.
Leadership continuity anchors the venture: CEO Sabrina Maniscalco, who maintains an adjunct professorship at Aalto University and holds credentials in quantum information science, bridges the gap between theoretical quantum research and commercial application development. This technical credibility, combined with sustained investor backing, positions Algorithmiq as a central player in translating quantum computing from theoretical potential into practical healthcare and chemistry solutions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.